What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

Despite having gone through this before with her first son, Yusof, and despite the doctors explaining that this was a gene ...

Haliza Md Kasim’s eyes widened. Despite having gone through this before with her first son, Yusof, and despite the doctors ...

REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

Shares of Regenxbio Inc . (NASDAQ: RGNX) surged 18.4% in pre-open trading Tuesday following the announcement of a strategic partnership with Nippon Shinyaku Co., ...

Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...

ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership ...

The face of the group, Billy J McBee, wrote to MPs from both sides of the House, as well as several government entities, including the Occupational Health and Safety Authority (OHSA) and the ...

January 11 - Hunter Dickinson had 14 points and 12 rebounds and No. 11 Kansas displayed stifling second-half defense to post a 54-40 Big 12 win over host Cincinnati on Saturday. Kansas (12-3 ...

On Tuesday 11 September 2001, suicide attackers seized US passenger jets and crashed them into two New York skyscrapers, killing thousands of people. What unfolded that day has had profound ...

Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).